Xuerong Bio-Technology's Q3 net profit surges nearly 300%

Shanghai Xuerong Bio-Technology Co. Ltd. reported a net profit attributable to shareholders of CNY 40,203,669.22 for Q3 2025, marking a substantial increase of 298.87% compared to the previous year. Despite a 6.30% decrease in operating revenue to CNY 534,255,898.88 for the quarter, the company's year-to-date net profit also improved, showing a 61.94% increase. Basic and diluted earnings per share for the quarter both rose by 275.00% to CNY 0.07.

The company's total assets decreased by 6.57% to CNY 3,601,440,662.94, while owners' equity attributable to shareholders surged by 55.22% to CNY 1,456,940,504.02 compared to the end of last year. This increase was significantly influenced by convertible bond conversions. Operating cash flow improved by 5.83% year-to-date, reaching CNY 248,156,943.68.

Noteworthy balance sheet changes include a 66.90% reduction in short-term borrowings, a 197.85% increase in notes payable, and a 140.78% rise in long-term borrowings. Selling expenses decreased by 34.51%, and financial expenses fell by 37.38% due to reduced borrowing and convertible bond conversions.